Leerink raised the firm’s price target on Nuvalent (NUVL) to $140 from $125 and keeps an Outperform rating on the shares. Nuvalent’s zidesamtinib has demonstrated a best in class profile in the competitive ROS1 landscape, driven by “unprecedented” durability and tolerability-attributes that have limited the commercial success of other ROS1 agents, the analyst tells investors in a research note. Leerink believes the drug has the potential to be a blockbuster in ROS1+ tumors across all lines of therapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent price target raised to $130 from $110 at H.C. Wainwright
- Nuvalent’s Zidesamib: Promising Best-in-Class ROS1 TKI with Strong Efficacy and Safety Profile
- Nuvalent Announces Positive Data for Zidesamtinib Trial
- Nuvalent Announces New Director and Annual Meeting Results
- Nuvalent’s Zidesamtinib: Promising Efficacy and Safety Drive Buy Rating